TYK Medicines to Present Five Novel Cancer Drug Programs at 2026 AACR Meeting

An announcement from TYK Medicines, Inc. Class H ( (HK:2410) ) is now available.

TYK Medicines, Inc., an international biopharmaceutical developer of next-generation kinase inhibitors for cancer, has advanced a portfolio of over ten innovative small-molecule therapies from early research through late-stage clinical development since its 2017 inception. The company is focused on addressing unmet oncology needs with targeted, more effective and safer anti-tumor drugs that span multiple mechanisms and tumor types.

The company announced that research progress and results from five innovative small-molecule anti-tumor drug candidates will be showcased in poster presentations at the 2026 American Association for Cancer Research annual meeting in San Diego. The projects, including CDK4, CDK7, EGFR/FAK PROTAC, PI3Kα and YAP-TEAD inhibitors, highlight TYK Medicines’ broad oncology pipeline and are expected to enhance its scientific visibility and credibility among global investors and researchers, though there is no assurance these candidates will ultimately reach the market.

The most recent analyst rating on (HK:2410) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.

More about TYK Medicines, Inc. Class H

TYK Medicines, Inc. is an international innovative biopharmaceutical company focused on researching and developing next-generation kinase inhibitors to address unmet clinical needs in cancer treatment. Founded in 2017, the company has built a pipeline of more than ten innovative anti-tumor products spanning from preclinical candidate stages to Phase III clinical trials, aiming to deliver more effective and safer cancer therapies.

Average Trading Volume: 2,563,558

Technical Sentiment Signal: Sell

Current Market Cap: HK$3.77B

For detailed information about 2410 stock, go to TipRanks’ Stock Analysis page.